ライフサイエンスコーパス: antiviral agent

1 ibosomal protein L13a, whereby it acts as an antiviral agent.

2 n and thus holds promise as a broad-spectrum antiviral agent.

3 peptide has the potential to be a potential antiviral agent.

4 o increase the antiviral potency of this new antiviral agent.

5 suggests that it might also be useful as an antiviral agent.

6 N treated with oral valacyclovir as the sole antiviral agent.

7 unct to the immunosuppressive regimen and an antiviral agent.

8 s, resistant strains become dependent on the antiviral agent.

9 replication advantage in the presence of the antiviral agent.

10 r HIV vaccine development and as a potential antiviral agent.

11 ited for the development of a broad spectrum antiviral agent.

12 use of exogenous interferon as a therapeutic antiviral agent.

13 velopment of MERS-CoV 3CL(pro) inhibitors as antiviral agents.

14 on therapies that contain only direct-acting antiviral agents.

15 NS2, to cyclosporine and other direct-acting antiviral agents.

16 vileged scaffold to obtain antibacterial and antiviral agents.

17 novel strategy for developing a new class of antiviral agents.

18 of viral RNA replication, and evaluation of antiviral agents.

19 probing norovirus replication and evaluating antiviral agents.

20 ication and also for screening/evaluation of antiviral agents.

21 side-derived drugs, including anticancer and antiviral agents.

22 avirus infection, require development of new antiviral agents.

23 supplies of affordable pandemic vaccines and antiviral agents.

24 Thus, there is a need to discover novel antiviral agents.

25 ts for combining it with other direct-acting antiviral agents.

26 ive treatment with antibiotics and influenza antiviral agents.

27 el CHC treatments that include direct-acting antiviral agents.

28 eptibility to first-generation direct-acting antiviral agents.

29 A/EMEA-approved gemcitabine represent potent antiviral agents.

30 useful for evaluating norovirus vaccines and antiviral agents.

31 despite the introduction of directly acting antiviral agents.

32 of protease inhibitors have been proposed as antiviral agents.

33 molecular clone has enabled discovery of new antiviral agents.

34 gy with broad implications for the design of antiviral agents.

35 a viable target for the development of novel antiviral agents.

36 d guidance to treat hospitalized adults with antiviral agents.

37 Tase becomes a rational target for designing antiviral agents.

38 ions for gene transfer or for development of antiviral agents.

39 of mTOR kinase inhibitors as broad-spectrum antiviral agents.

40 in the endosome may lead to novel classes of antiviral agents.

41 interactions is important for the design of antiviral agents.

42 nd those that differ in their sensitivity to antiviral agents.

43 mbers of an important class of antitumor and antiviral agents.

44 Viruses often evolve resistance to antiviral agents.

45 HIV-1 may become resistant to this class of antiviral agents.

46 esigning carbohydrate-based HIV vaccines and antiviral agents.

47 viral replication and second on multiple HCV antiviral agents.

48 n attractive strategy for the development of antiviral agents.

49 interactions and also serve as potential new antiviral agents.

50 n potentially be developed as broad-spectrum antiviral agents.

51 usly uncharacterized class of broad-spectrum antiviral agents.

52 vention, and efficient use of antibiotic and antiviral agents.

53 that interfere with this change may be novel antiviral agents.

54 for which we have a very limited arsenal of antiviral agents.

55 on, elucidating mutant function, and testing antiviral agents.

56 V replication mechanisms and for testing new antiviral agents.

57 processing of nucleoside-type anticancer and antiviral agents.

58 pathways represent a promising new class of antiviral agents.

59 ew targets that can be used to develop novel antiviral agents.

60 n, length of intensive care stay, and use of antiviral agents.

61 development of several small molecule-based antiviral agents.

62 oven to be successful in producing effective antiviral agents.

63 cells and have potential for development as antiviral agents.

64 ting novel nucleoside analogues as potential antiviral agents.

65 ruses and may lead to the rational design of antiviral agents.

66 ed an all-oral regimen of >/=2 direct-acting antiviral agents.

67 ve CMV viraemia control without the need for antiviral agents.

68 novel insight into the utility of statins as antiviral agents.

69 essed prospectively in the era of new direct antiviral agents.

70 ave hampered the development of vaccines and antiviral agents.

71 lity in combination with other direct acting antiviral agents.

72 ormation for future clinical trials of newer antiviral agents.

73 all-oral regimen of 2 or more direct-acting antiviral agents.

74 to basic virology and the development of new antiviral agents.

75 ximum risk exposures and were given PEP with antiviral agents.

76 regimens of recently approved direct-acting antiviral agents.

77 iochemical relapse were re-treated with oral antiviral agents (11 during the first 18 months and 4 af

78 and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC6

79 ia, were equally likely to receive influenza antiviral agents (78% vs 79%) but less likely to receive

80 of pronucleotide (ProTide) technology to the antiviral agent abacavir (Ziagen), used for the treatmen

81 brain penetration of the P-gp substrate and antiviral agent abacavir, in conjunction with a traceles

82 irs in the brain necessitates penetration of antiviral agents across the blood-brain barrier (BBB), a

83 de effects are rarely reported with the oral antiviral agents active against HBV.

84 to investigate the association of individual antiviral agents (acyclovir, ganciclovir, and valgancicl

85 s also a cap-binding protein and is a potent antiviral agent against many plant, animal, and human vi

86 nt attractive targets for the development of antiviral agents against chronic HBV infection.

87 e use of modified nanoparticles as potential antiviral agents against diseases such as herpes simplex

88 In an effort toward discovery of novel antiviral agents against HBV, a group of benzamide (BA)

89 ors and warranted for further development as antiviral agents against HBV.IMPORTANCE HBV core protein

90 a potential path to the generation of novel antiviral agents against HCV infection.

91 de, nucleotide analogs have emerged as novel antiviral agents against hepatitis B virus.

92 The development of specifically targeted antiviral agents against hepatitis C is a major therapeu

93 ism may help in the rational design of novel antiviral agents against HIV.

94 Antiviral agents against measles virus are not commercia

95 refusion F-specific VHHs represent promising antiviral agents against RSV.

96 lymerase and will aid further development of antiviral agents against RSV.

97 hibitors of ErbB-1 kinases might function as antiviral agents against smallpox.

98 uld be cured by treatment with direct-acting antiviral agents alone in the absence of interferon.

99 ew classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted an

100 monstrate that favipiravir, a broad-spectrum antiviral agent and leading treatment option for influen

101 ROUND & AIMS: Daclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is i

102 Daclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is i

103 Appropriate use of antiviral agents and improving influenza immunization co

104 is rapidly progressing toward generation of antiviral agents and increasingly effective vaccines.

105 h-risk patients to prioritize the use of new antiviral agents and intensive screening.

106 e many current limitations of treatment with antiviral agents and of vaccine production and immunogen

107 erties which augment the antiviral effect of antiviral agents and offer the potential to suppress the

108 he allosteric inhibitors of IN are promising antiviral agents and provide new information on their me

109 ed patients who received three direct-acting antiviral agents and ribavirin for 8 weeks and those who

110 evaluate multiple regimens of direct-acting antiviral agents and ribavirin in patients with HCV geno

111 titargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of

112 In this phase 2b study, all-oral regimens of antiviral agents and ribavirin were effective both in pa

113 l platform for development of a new class of antiviral agents and that inhibitory beta-peptides will

114 e deployment of resources such as stockpiled antiviral agents and vaccines.

115 us, and the prospects for the development of antiviral agents and vaccines.

116 as well as to facilitate the development of antiviral agents and vaccines.

117 replication cycles has led to many existing antiviral agents and will undoubtedly continue to be the

118 inclusion (with interferon then with direct antiviral agents) and underwent an ultrasound examinatio

119 that rPMP prodrugs may be highly efficacious antiviral agents, and provide a new tool to determine th

120 gs and biocides, including antimicrobial and antiviral agents, anticancer drugs, photodynamic therapy

121 urrent therapies with all-oral direct-acting antiviral agents are associated with high rates of susta

122 Effective antiviral agents are difficult to develop because of the

123 Direct-acting antiviral agents are highly efficient treatment options

124 Survival data with direct-acting antiviral agents are not available.

125 comes, with limited evidence that first-line antiviral agents are superior to lamivudine.

126 In the event of a pandemic, antiviral agents are the mainstay for treatment, but bro

127 Corticosteroids and antiviral agents are widely used to treat the early stag

128 tions for the rational design of vaccine and antiviral agents as well as for understanding viral trop

129 It may prove useful as an antiviral agent, as a probe to study HCV replication, an

130 of this enzyme are potential broad-spectrum antiviral agents, as inhibition of this enzyme results i

131 SA is considered an attractive antitumor and antiviral agent because of its ability to selectively ex

132 virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzyme target of thes

133 infection, the addition of the direct-acting antiviral agent boceprevir to standard treatment with pe

134 od can be used to identify not only putative antiviral agents, but also cellular regulators of viral

135 Antiviral agents can target viral or host gene products

136 te pronucleotide (ProTide) technology to the antiviral agent carbocyclic L-d4A (L-Cd4A).

137 ccination regimen comprised of Dryvax and an antiviral agent, cidofovir, could reduce vaccinia viral

138 mutations conferring resistance to multiple antiviral agents co-locate on the same HBV genome in viv

139 mutations conferring resistance to multiple antiviral agents co-locate on the same viral genome, sug

140 enging pursuit, hallmarked by the paucity of antiviral agents currently prescribed.

141 There is a growing armamentarium of antiviral agents currently under development, although p

142 irus (HCV) patients who fail directly-acting antiviral agent (DAA)-based treatment is unknown.

143 Direct acting antiviral agents (DAA) are highly effective yet expensiv

144 elp to improve the efficacy of direct-acting antiviral agents (DAA) in the treatment of HCV-infected

145 enal transplant population but direct acting antiviral agents (DAA) provide an effective cure of HCV

146 Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV)

147 in development, including both direct-acting antiviral agents (DAAs) and host cofactor inhibitors.

148 Currently, direct-acting antiviral agents (DAAs) are evaluated in clinical trials

149 Direct-acting antiviral agents (DAAs) are highly effective and well to

150 Direct-acting antiviral agents (DAAs) are used increasingly to treat h

151 treatment with investigational direct-acting antiviral agents (DAAs) has not been extensively studied

152 tment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options

153 n antiretroviral drugs and HCV direct-acting antiviral agents (DAAs) must be carefully considered.

154 Direct-acting antiviral agents (DAAs) represent the standard of care f

155 The new interferon-free direct antiviral agents (DAAs) showed high efficacy and safety,

156 opments in directed use of new direct-acting antiviral agents (DAAs) to eliminate circulating HCV bef

157 eral new HCV therapies, called direct-acting antiviral agents (DAAs), are available that achieve cure

158 ree regimens that consist of directly acting antiviral agents (DAAs), which demonstrate improved effi

159 ombination therapy consisting of only direct-antiviral agents (DAAs).

160 , which is the major target of direct-acting antiviral agents (DAAs).

161 antially since the approval of direct-acting antiviral agents (DAAs).

162 ociated variants for all three direct-acting antiviral agents (DAAs); however, in all but 1 patient w

163 ')pA(3',5')p], c[G(3',5')pA(3',5')p] and the antiviral agent DMXAA, leading to similar "closed" confo

164 These data suggest that human studies using antiviral agents during critical illness are warranted.

165 implications, suggesting that application of antiviral agents early in the disease course, even at a

166 luenza A viruses necessitates development of antiviral agents effective against various antigenic sub

167 splant with little expansion in the range of antiviral agents effective in treatment of CMV.

168 d strategy but with expanded distribution of antiviral agents (expanded prophylaxis strategy), and 3)

169 ta indicate that FIT-039 has potential as an antiviral agent for clinical therapeutics.

170 gest that TAT-Kalpha2 peptide is a potential antiviral agent for controlling emerging or re-emerging

171 dy raise the possibility of a broad spectrum antiviral agent for influenza virus and HPIVs.

172 tial for further development as an effective antiviral agent for treatment of HIV-1 infection.

173 To shorten the course of direct-acting antiviral agents for chronic hepatitis C virus (HCV) inf

174 iral therapy for HIV and preliminary data on antiviral agents for hepatitis C virus infection.

175 eptual platform to design nanoparticle-based antiviral agents for HIV-1 specifically and putatively f

176 These inhibitors are also effective antiviral agents for HIV-2-infected cells.

177 logs provides an approach for creating novel antiviral agents for IAV infections.

178 as K04 may have potential as broad-spectrum antiviral agents for prevention and treatment of HCV inf

179 e analogue 4'-azidouridine to generate novel antiviral agents for the inhibition of hepatitis C virus

180 The use of available antiviral agents for the prevention of cytomegalovirus (

181 ently approved a number of new direct-acting antiviral agents for the treatment of chronic hepatitis

182 d for safe, effective, and readily available antiviral agents for treatment and prevention of acute E

183 ion, digoxin and digitoxin show potential as antiviral agents for treatment of serious adenovirus inf

184 s relatively resistant to the broad-spectrum antiviral agent foscarnet.

185 Treatment of these mice with the antiviral agent, ganciclovir, conditionally ablates prol

186 Although treatment with antiviral agents has proven a very effective way to impr

187 Five oral antiviral agents have been approved for the treatment of

188 spite its clinical significance, no specific antiviral agents have been approved for treatment of HMP

189 While highly efficacious directly-acting antiviral agents have been developed in recent years, th

190 Efforts to discover and develop poliovirus antiviral agents have been ongoing in earnest since the

191 Chemotherapy and antiviral agents have been used.

192 The CMV immunoglobulin (CMVIG) and antiviral agents have complementary modes of action.

193 Direct-acting antiviral agents have not been studied exclusively in pa

194 Ebola PEP, but newly developed experimental antiviral agents have potential advantages.

195 Second generation direct-acting antiviral agents have revolutionized therapy, with susta

196 line and estimating in vivo effectiveness of antiviral agents; however, it has not been used to chara

197 may be a therapeutic window in which use of antiviral agents (i.e., zidovudine and raltegravir) may

198 ay be considered a target for development of antiviral agents.IMPORTANCE Herpes simplex virus is a ma

199 s in designing studies to evaluate influenza antiviral agents in a hospitalized setting.

200 ment of several million courses of influenza antiviral agents in a targeted prophylaxis strategy may

201 New evidence on the safety of antiviral agents in children and studies on intervention

202 The efficacy of directly acting antiviral agents in interferon-free regimens for the tre

203 and, thus, makes it feasible to investigate antiviral agents in mammalian cells.

204 Clinical trials of direct-acting antiviral agents in patients chronically infected with h

205 he duration of prophylaxis or treatment with antiviral agents in those who have achieved CMV-specific

206 to sensitize EBV(+) human lymphoma cells to antiviral agents in vitro.

207 Traditional antiviral agents interfere with viral proteins or functi

208 require an adaptive mechanism to convert the antiviral agent into a beneficial growth factor.

209 primary virological end points in studies of antiviral agents involving patients who are hospitalized

210 ombination of SOF and a second direct-acting antiviral agent is highly effective in TN patients with

211 A safe broad-spectrum antiviral agent is needed to treat this unmet medical ne

212 revention of virus disease by vaccination or antiviral agents is difficult to achieve.

213 nucleoside and non-nucleoside inhibitors as antiviral agents is discussed with particular emphasis o

214 s well as their potential use as targets for antiviral agents is discussed.

215 C virus (HCV) genotype 1 with direct-acting antiviral agents is often accompanied by the emergence o

216 lternatives to annual influenza vaccines and antiviral agents licensed for mitigating influenza infec

217 Antiviral agents may also have a potential role in the m

218 , including blockade of multiple pathways or antiviral agents, need to be sought for this high unmet

219 tment (using boceprevir as the direct-acting antiviral agent) of those with chronic HCV infection cos

220 The impact of the individual antiviral agent on long-term outcome was further evaluat

221 ponse can be achieved with two direct-acting antiviral agents only.

222 ll-type-specific effects upon treatment with antiviral agents, opening additional avenues of research

223 n in the recipient can be prevented by using antiviral agents or by boosting protective anti-HBs tite

224 r control: Treating symptomatic persons with antiviral agents or encouraging home isolation would be

225 selected and characterized as candidates for antiviral agents or reagents for standardization of vacc

226 on when administered in combination with the antiviral agent oseltamivir.

227 e presence of neutralizing antibodies and an antiviral agent, Oseltamivir, influenza virus can exploi

228 As a consequence, the importance of antiviral agents, particularly neuraminidase (NA) inhibi

229 eeks of SOF along with another direct-acting antiviral agent plus RBV achieved SVR12-9 of 9 (100%) of

230 iate to numerous 8-8'-lignans, including the antiviral agent podophyllotoxin in Podophyllum species a

231 d facilitate the discovery of a new class of antiviral agents providing HIV-1 patients with broader t

232 NS3/4A protease inhibitor) are direct-acting antiviral agents recently approved in the United States

233 NS3/4A protease inhibitor) are direct-acting antiviral agents recently approved in the United States

234 With the availability of direct-acting antiviral agents, recently approved therapies and those

235 r evaluation of the three-drug direct-acting antiviral agent regimen of grazoprevir 100 mg plus ruzas

236 Many other direct-acting antiviral agents representing several classes, as well a

237 HIV-1 replication in the presence of antiviral agents results in evolution of drug-resistant

238 success, the addition of the broad-spectrum antiviral agent ribavirin greatly improved responses.

239 n to a similar extent as the clinically used antiviral agent, ribavirin.

240 Moreover, treatment with cidofovir, a potent antiviral agent, robustly inhibits the sT-mediated enhan

241 ieve its potential as a broad-spectrum human antiviral agent should be explored.

242 RTI-resistant HIV-1 suggests that additional antiviral agents should be included in NNRTI-based micro

243 Two new oral antiviral agents, simeprevir and sofosbuvir, have alread

244 BMS-791325 is a novel direct antiviral agent specifically targeting HCV NS5B, an RNA-

245 able (ribavirin) or investigational (DAS181) antiviral agents still needs to be determined.

246 In that case, an antiviral agent stockpile on the order of 100,000 to 1 m

247 Direct-acting antiviral agents suppress hepatitis B virus (HBV) load,

248 Antiviral agents suppress hepatitis B virus (HBV) replic

249 the most promising approaches, including new antiviral agents, symptomatic or immunomodulatory drugs,

250 and show promise for further development of antiviral agents targeting highly resistant PR mutants.

251 ognition with PRNTase but also for designing antiviral agents targeting this enzyme.

252 (HCV), the combination of the direct-acting antiviral agent telaprevir, pegylated-interferon alfa (P

253 Additionally, IFN-lambda is a potent antiviral agent that has certain advantages for clinical

254 mong all family members, which suggests that antiviral agents that block these steps might be effecti

255 The development of direct-acting antiviral agents that can cure a chronic hepatitis C vir

256 ighlight a desperate need for broad-spectrum antiviral agents that can effectively control infections

257 Owing to the wide availability of antiviral agents that effectively suppress HBV replicati

258 yanobacterial lectin, exemplifies a class of antiviral agents that inhibit HIV by binding to the high

259 t in most PEL cells and, hence, resistant to antiviral agents that inhibit lytic replication.

260 nofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic

261 Interferons are important antiviral agents that modulate both the initial and pers

262 Currently there are no approved antiviral agents that reduce or eliminate HPV and revers

263 sistant phenotypes that could be selected by antiviral agents that specifically target capsid assembl

264 uidelines for developing new N protein-based antiviral agents that target CoVs.

265 ysiological conditions and identification of antiviral agents that target HBc.

266 s are potentiated in combination with direct antiviral agents that target HBV-DNA polymerase.

267 It is a challenge to develop direct-acting antiviral agents that target the nonstructural protein 3

268 Antiviral agents that target this novel aspect of GPC me

269 ing drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinic

270 Resumption of direct-acting antiviral agent therapy after a temporary interruption a

271 ased dual, triple, or all-oral direct acting antiviral agent therapy, respectively, whereas 79% of pa

272 n and the potential use of 25HC as a natural antiviral agent to combat ZIKV infection and prevent ZIK

273 lving a mechanism to productively utilize an antiviral agent to stimulate its fitness above the uninh

274 No licensed antiviral agent to treat DENV infections is currently av

275 Discovery and development of effective antiviral agents to combat hepatitis C virus (HCV) is th

276 We focused on those treated with antiviral agents to explore the effect of early treatmen

277 ere is an urgent need for safe and effective antiviral agents to prevent transmission of HIV.

278 from the addition of multiple direct-acting antiviral agents to their treatment regimen.

279 The development of direct-acting antiviral agents to treat HCV has focused predominantly

280 er development of BDAA or its derivatives as antiviral agents to treat yellow fever.

281 Despite the availability of new antiviral agents, treatment remains suboptimal.

282 Prophylaxis for CMV using antiviral agents (typically oral valganciclovir or intra

283 (NNRTIs) are potent and commonly prescribed antiviral agents used in combination therapy (CART) of h

284 iety of levels and combinations of influenza antiviral agents, vaccines, and modified social mobility

285 Sensitivity to antiviral agents was evaluated.

286 PEP with antiviral agents was given to health-care workers assess

287 grase stimulator (IS) compounds as potential antiviral agents, we have developed a nonradioactive ass

288 the enzyme by dimerization may be potential antiviral agents, we investigated the monomer-dimer equi

289 been treated previously with a direct-acting antiviral agent were assigned randomly to groups given s

290 RECENT FINDINGS: Two new directly acting antiviral agents were approved in 2011 for use in hepati

291 onse was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2

292 ng therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had

293 try who started treatment with direct-acting antiviral agents while awaiting LT were identified retro

294 Other antiviral agents will be available during 2014.

295 Entecavir is a potent antiviral agent with a low rate of drug resistance in nu

296 There are no FDA-licensed vaccines or antiviral agents with activity against RVFV, and details

297 substituent provided a number of more potent antiviral agents with IC(50) values ranging to 2.5 muM.

298 and monitoring of herpesvirus infections and antiviral agents with improved efficacy in prophylaxis a

299 ed patients who received three direct-acting antiviral agents (with the ABT-450/r dose administered a

300 ents (78% vs 79%) but less likely to receive antiviral agents within </=2 days of illness onset (28%